Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neuphoria Therapeutics (NEUP) Equity Average (2022 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Equity Average for 4 consecutive years, with $21.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Equity Average rose 36.97% to $21.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $21.1 million, a 36.97% increase, with the full-year FY2023 number at $31.5 million, changed N/A from a year prior.
  • Equity Average was $21.1 million for Q4 2025 at Neuphoria Therapeutics, up from $15.8 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $31.5 million in Q2 2023 to a low of $15.4 million in Q4 2024.
  • A 4-year average of $21.3 million and a median of $20.5 million in 2025 define the central range for Equity Average.
  • Biggest YoY gain for Equity Average was 36.97% in 2025; the steepest drop was 19.66% in 2025.
  • Neuphoria Therapeutics' Equity Average stood at $24.5 million in 2022, then rose by 28.21% to $31.5 million in 2023, then tumbled by 51.02% to $15.4 million in 2024, then surged by 36.97% to $21.1 million in 2025.
  • Per Business Quant, the three most recent readings for NEUP's Equity Average are $21.1 million (Q4 2025), $15.8 million (Q3 2025), and $22.5 million (Q2 2025).